Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 775 shares of the business's stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $17.35, for a total transaction of $13,446.25. Following the completion of the sale, the insider directly owned 55,334 shares of the company's stock, valued at approximately $960,044.90. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Mark Hopman also recently made the following trade(s):
- On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total transaction of $7,015.20.
- On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27.
- On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total transaction of $680,620.20.
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97.
Beta Bionics Stock Down 5.5%
Shares of NASDAQ BBNX traded down $0.96 during trading on Friday, hitting $16.35. The company had a trading volume of 660,832 shares, compared to its average volume of 1,051,882. The stock has a fifty day simple moving average of $19.04 and a two-hundred day simple moving average of $15.19. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm has a market capitalization of $735.59 million, a price-to-earnings ratio of -9.91 and a beta of 3.39.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The firm had revenue of $32.01 million during the quarter. On average, analysts anticipate that Beta Bionics, Inc. will post -2.02 earnings per share for the current year.
Institutional Trading of Beta Bionics
Large investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new position in Beta Bionics in the 2nd quarter worth approximately $2,524,000. Bank of America Corp DE purchased a new stake in shares of Beta Bionics in the second quarter valued at approximately $8,566,000. Man Group plc purchased a new stake in shares of Beta Bionics in the second quarter valued at approximately $419,000. Legal & General Group Plc purchased a new stake in shares of Beta Bionics in the second quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Beta Bionics in the second quarter valued at approximately $172,000.
Key Beta Bionics News
Here are the key news stories impacting Beta Bionics this week:
- Negative Sentiment: The securities lawsuit covers investors who purchased Beta Bionics shares between July 30, 2025, and February 24, 2026. The claims reportedly relate to alleged disclosures concerning the FDA’s concerns about the company’s iLet automated insulin-delivery system and the impact of those revelations on the stock. The allegations have not been proven. Hagens Berman securities class-action announcement
- Negative Sentiment: Additional notices cite allegations that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints. If substantiated, such claims could increase regulatory, litigation, and reputational risks for the company. SueWallSt Beta Bionics lawsuit notice
- Negative Sentiment: The high volume of investor-law-firm announcements keeps attention focused on legal exposure and prior share-price losses, weighing on investor confidence. The lead-plaintiff deadline is November 3, 2026. Kaplan Fox lead-plaintiff deadline notice
- Neutral Sentiment: Insider Mark Hopman sold 775 shares for approximately $13,446, reducing his direct ownership by 1.38%. Because the sale was small relative to his remaining 55,334 shares, it is a modest signal but may add some pressure to sentiment. SEC insider transaction filing
Wall Street Analyst Weigh In
BBNX has been the subject of several research reports. William Blair assumed coverage on Beta Bionics in a research note on Friday, August 21st. They set a "market perform" rating for the company. Wall Street Zen upgraded Beta Bionics from a "sell" rating to a "hold" rating in a research report on Saturday, September 19th. Leerink Partners lifted their price target on Beta Bionics from $24.00 to $27.00 and gave the stock an "outperform" rating in a research note on Monday, September 14th. Barclays started coverage on Beta Bionics in a research report on Tuesday, October 6th. They set an "overweight" rating and a $30.00 price target for the company. Finally, The Goldman Sachs Group increased their price objective on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $24.00.
Read Our Latest Analysis on Beta Bionics
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.
The iLet Bionic Pancreas uses continuous glucose monitoring data and the company's dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person's body weight and meal announcements as key inputs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
